TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna ") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“ Ceapro ”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock... Read More

ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and governance conflicts appear to have been reasonably managed.” ISS states in its Ceapro FOR recommendation that “The arrangement is the result of arm's length negotiations between the parties and carries sound strategic logic.” Aeterna... Read More

EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business. On December 14, 2023, the Company announced it entered into a definitive agreement to combine operations with Aeterna Zentaris Inc. (“ Aeterna Zentaris ”), a TSX and Nasdaq listed specialty biopharmaceutical company, in an all-stock... Read More

EDMONTON, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“ Ceapro ” or the “ Company ”) is pleased to announce that it has mailed and filed a management information circular dated February 9, 2024 and related meeting materials (collectively, the “ Meeting Materials ”) for the special meeting (the “ Meeting ”) of Securityholders (as defined below) to be held on March 12, 2024, called to... Read More

Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute No adverse reactions observed, and study can continue as planned EDMONTON, Alberta, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the... Read More

Product development focused on the production of powder formulations of oat beta glucan and avenanthramides for cosmeceuticals market Technology development focused on the PGX pilot scale units Q3 2023 sales of $2,619,000 vs $3,845,000 in Q3 2022; YTD sales of $7,983,000 vs $15,517,000 Ended the quarter with $11.4 million in cash allowing funding for planned pipeline and technology developments EDMONTON, Alberta, Nov. 29,... Read More

Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute Screening of healthy subjects is now underway Phase 1-2a study to provide valuable insights into the safety and activity of avenanthramides in managing conditions related to inflammation EDMONTON, Alberta, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused... Read More

PGX processing unit with a 10X (100 L) vessel capacity to be installed and tested at NATEX pilot testing facility in Austria Yeast beta glucan (YBG) to be the first bio active to be processed at this location EDMONTON, Alberta, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active... Read More

$5.5 million first six-month 2023 sales vs. $11.7 million for the same period in 2022; sales lagging by one quarter due to stocking campaign by one major customer in 2022 and further Marketplace reorganization Ended the quarter with $11.3 million in cash allowing funding for planned pipeline and technology developments Ongoing strategic corporate discussions progressing and continued planning for uplisting to Nasdaq... Read More

Exclusive agreement extended from 3 to 5 years until December 31, 2026 Supply and distribution agreement provides Symrise with exclusivity for several major key international customers in the cosmetic market Offering of new preservative free dry product formulation for oat beta glucan EDMONTON, Alberta, Aug. 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage... Read More

New studies to focus on speed of healing and molecular profiling of tissue regeneration induced by oat-derived bioactive products EDMONTON, Alberta, July 18, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the expansion... Read More

EDMONTON, Alberta, July 05, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro and Dr. Vincent W. Li, Chief Operating Officer and Scientific Director of... Read More

EDMONTON, Alberta, June 07, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors were elected to serve for a one-year term at its Annual General and Special Meeting of Shareholders held on June... Read More

Q1 2023 sales of $3,500,000 vs $6,172,000 in Q1 2022 Ended the quarter with $12.6 million in cash allowing funding for planned pipeline development EDMONTON, Alberta, May 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today... Read More

Results from the completed Collaborative Health Research Projects (CHRP) study with McMaster University presented at the American Thoracic Society (ATS) International Conference Data demonstrated that PGX-processed yeast beta glucan (PGX-YBG) is respirable and able to safely and reliably reprogram macrophages in the lungs in pre-clinical mouse models – Company advancing toward go/no-go milestone for further evaluation of... Read More

Data presented at 2023 Annual Meeting of the Wound Healing Society showed statistically significant results characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive products on wound healing and tissue regeneration Tissue treated with Avenanthramides (“AVE”) and oat beta glucan (“BG”) bioactives healed to become more normal skin as compared to untreated scar tissue EDMONTON, Alberta, May 03, 2023 (GLOBE... Read More

EDMONTON, Alberta, April 27, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the appointment of Michel (Mitch) Regnier as Senior Vice President, Technical Operations, effective May 1, 2023. Mr. Regnier is an... Read More

2022 marks Ceapro’s best performance in Company history with record sales of $18,800,000 compared to $17,200,000 for 2021, representing a 10% increase year over year Net profit after tax of $4,400,000 for the full year of 2022 compared to $3,400,000 in 2021, a year over year increase of 31% R&D activities focused on advancement toward avenanthramide Phase 1-2a clinical study, development of innovative delivery systems with... Read More

EDMONTON, Alberta, March 23, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the abstract titled, “ Reprogramming Rogue Macrophages: Yeast Beta-Glucan Microparticles as a Macrophage Modulator for Lung Fibrosis, ”... Read More

Oral presentation to highlight unique results from pre-clinical studies characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive products on angiogenesis, wound healing and tissue regeneration EDMONTON, Alberta, March 08, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active... Read More

EDMONTON, Alberta, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technologies for healthcare and cosmetic industries, announced today that it has been named as one of the top performers on the TSX Venture Exchange. The 2023 TSX Venture 50™... Read More

EDMONTON, Alberta, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, M.Sc., MBA, President and Chief Executive Officer of Ceapro, will present at the Virtual Investor 2023 Companies to Watch... Read More

EDMONTON, Alberta, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the granting of stock options (“options”) to employees, officers and directors of the Company. Options to purchase 740,000 common shares were... Read More

Ceapro is pioneering approach with a natural product as a potential anti-inflammatory Clinical study to be conducted with the Montreal Heart Institute led by MHI’s Montreal Health Innovations Coordinating Center (MHICC) EDMONTON, Alberta, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active... Read More